Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

DiaMedica Therapeutics (DMAC) Equity Average (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Equity Average readings, the most recent being $51.7 million for Q1 2026.

  • Quarterly Equity Average rose 38.4% to $51.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $51.7 million through Mar 2026, up 38.4% year-over-year, with the annual reading at $48.4 million for FY2025, 5.51% up from the prior year.
  • Equity Average hit $51.7 million in Q1 2026 for DiaMedica Therapeutics, down from $53.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $57.7 million in Q3 2023 and bottomed at $29.4 million in Q1 2023.
  • Average Equity Average over 5 years is $43.6 million, with a median of $43.4 million recorded in 2023.
  • The largest annual shift saw Equity Average surged 80.57% in 2022 before it crashed 38.73% in 2025.
  • DiaMedica Therapeutics' Equity Average stood at $33.5 million in 2022, then soared by 59.46% to $53.3 million in 2023, then dropped by 16.88% to $44.3 million in 2024, then rose by 21.48% to $53.9 million in 2025, then decreased by 4.07% to $51.7 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Equity Average are $51.7 million (Q1 2026), $53.9 million (Q4 2025), and $39.4 million (Q3 2025).